Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Samrat PharmachemBOM:530125 -3.60%69 Cyclically Adjusted PS Ratio is 0.31 as of Aug. 26, 2026, which is 53% below its 10-year median of 0.66. GuruFocus rates BOM:530125 with a GF Score™ of 69/100 and a GF Value™ of ₹362.16 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,274 Chemicals companies, Samrat Pharmachem ranks better than 87.52% on this metric.
The historical rank and industry rank for Samrat Pharmachem's Cyclically Adjusted PS Ratio or its related term are showing as below:
BOM:530125'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.26 Med: 0.66 Max: 2.6
Current: 0.32
During the past years, Samrat Pharmachem's highest Cyclically Adjusted PS Ratio was 2.60. The lowest was 0.26. And the median was 0.66.
BOM:530125's Cyclically Adjusted PS Ratio is ranked better than 87.52% of 1274
companies
in the Chemicals industry
Industry Median: 1.33
vs BOM:530125: 0.32
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Samrat Pharmachem's adjusted revenue per share data for the three months ended in Mar. 2026 was ₹232.276. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹755.02 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Samrat Pharmachem (BOM:530125) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Samrat Pharmachem Cyclically Adjusted PS Ratio Related Terms
Samrat Pharmachem Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Samrat Pharmachem's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samrat Pharmachem Cyclically Adjusted PS Ratio Chart
BOM:530125 vs DOW: Cyclically Adjusted PS Ratio Comparison
For the Chemicals subindustry, Samrat Pharmachem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samrat Pharmachem Cyclically Adjusted PS Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Samrat Pharmachem's Cyclically Adjusted PS Ratio falls into.
Samrat Pharmachem Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Samrat Pharmachem's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.31 mean?
Samrat Pharmachem (BOM:530125) has a Cyclically Adjusted PS Ratio of 0.31 as of Aug. 26, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Samrat Pharmachem and its competitors. This is 53% below median its historical median of 0.66. Over the past decade, Samrat Pharmachem's Cyclically Adjusted PS Ratio has ranged from 0.26 to 2.60. According to the industry distribution chart, Samrat Pharmachem ranks #159 out of 1274 companies in the Chemicals industry, placing it in the top 12.5%.
Is Samrat Pharmachem's Cyclically Adjusted PS Ratio too high?
Samrat Pharmachem's current Cyclically Adjusted PS Ratio of 0.31 is 53% below median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 2.60. The Chemicals industry median Cyclically Adjusted PS Ratio is 1.33. Samrat Pharmachem's value of 0.31 is 76.7% below this industry median. Based on the distribution chart, Samrat Pharmachem ranks #159 out of 1274 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Samrat Pharmachem has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's Cyclically Adjusted PS Ratio compare to DOW?
According to the Chemicals industry distribution chart, Samrat Pharmachem ranks #159 out of 1274 companies for Cyclically Adjusted PS Ratio. This places Samrat Pharmachem in the top 13% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PS Ratio is 1.33. Samrat Pharmachem's value of 0.31 is 76.7% below this benchmark. Historically, Samrat Pharmachem's own Cyclically Adjusted PS Ratio has ranged from 0.26 to 2.60 over the past decade. While the company's 10-year median is 0.66 vs. the industry median of 1.33, Samrat Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Chemicals company?
The median Cyclically Adjusted PS Ratio among Chemicals companies is 1.33, based on 1,274 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Samrat Pharmachem's current Cyclically Adjusted PS Ratio of 0.31 is 76.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Samrat Pharmachem and its competitors. For the Chemicals industry, the median Cyclically Adjusted PS Ratio is 1.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samrat Pharmachem's current Cyclically Adjusted PS Ratio is 0.31, which is 53% below median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.16, compared to a current price of ₹236.95 — trading 34.6% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.31, which is 53% below median its 10-year median of 0.66 and 76.7% below the Chemicals industry median of 1.33. Samrat Pharmachem's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current Cyclically Adjusted PS Ratio is 0.31 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹236.95 is trading 34.6% below its estimated GF Value™ of ₹362.16.
GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:530125:
Cyclically Adjusted PS Ratio: 0.31 (53% below median its 10-year median of 0.66)
GF Value™: ₹362.16 vs. price of ₹236.95 (34.6% below fair value)
Industry Position: 76.7% below the Chemicals median (#159 of 1274)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
69GF Score
Get the complete analysis for BOM:530125
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
